Viking Phase II Update Shows Sustained Response After Treatment’s End

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Currently running a Phase IIb NASH trial with VK2809, Viking reported at EASL that 16-week data in a Phase II study of NAFLD patients showed sustained liver fat reduction after treatment ended.

SC2008_Fatty Liver_274834199_1200.jpg
Viking thinks its THR beta agonist for NASH could be best in class

Additional Phase II data presented at the virtual European Association for the Study of the Liver meeting on 28 August suggest that Viking Therapeutics, Inc.’s VK2809 could emerge as a best-in-class treatment option for non-alcoholic steatohepatitis (NASH) patients, although it is competing directly with Madrigal Pharmaceuticals, Inc.’s Phase III resmetirom in the thyroid hormone receptor beta (THRβ) agonist class.

Previously, Viking unveiled Phase II data showing that its THRβ agonist yielded a 58% reduction in hepatic fat from baseline...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D